# Community Healthcare Trust Incorporated (CHCT)

> Source: Nexqual · https://nexqual.com/CHCT · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Community Healthcare Trust Incorporated (CHCT), nexqual.com/CHCT" · informational, not investment advice.

**Price:** USD 12.93 (+2.29% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 12.64 · day 12.76–13 · 52w 12.58–19.17 · market cap $370M · NYQ

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $125M, net income $21.0M (16.8% margin), free cash flow $38.7M (SEC filings).
- Valuation: P/E 17.7x (avg 86.7x at the last 2 fiscal year-ends), net debt $557M.
- 1 of 80 tracked superinvestors hold CHCT (13F, Q2 2026): 0 new, 0 added, 1 reduced, 0 unchanged.
- Insider open-market purchases, last ~7 months: 2 Form 4 filings, $273K; 0 by opportunistic insiders, 0 by routine insiders.
- Total return with dividends: 1Y +3.1% vs S&P 500 +14.9%; 5Y -59.3% vs S&P 500 +80.3%.
- Next earnings: 2026-11-03, EPS estimate USD —, revenue estimate $31.5M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $90.6M | $97.7M | $113M | $116M | $121M | $125M |
| Net income | $22.5M | $22.0M | $7.7M | -$3.2M | $5.1M | $21.0M |
| EPS (diluted) | $0.87 | $0.81 | $0.20 | -$0.23 | $0.08 | — |
| Free cash flow | $49.1M | $49.9M | $42.4M | $34.2M | $35.9M | $38.7M |
| Net margin | 24.8% | 22.5% | 6.8% | -2.7% | 4.2% | 16.8% |
| Revenue growth | +19.7% | +7.8% | +15.5% | +2.6% | +4.7% | — |
| Cash + short-term investments | $2.4M | $11.2M | $3.5M | $4.4M | $3.3M | — |
| Total debt | $266M | $353M | $403M | $486M | $532M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 17.7x · P/S 3.0x · EV/Sales 7.4x · P/FCF 9.6x · P/B 0.9x · FCF yield 10.45% · Earnings yield 5.66% · Dividend yield (paid, TTM) 14.69% · Net debt $557M · EV $927M
P/E at fiscal year-ends: Dec 2025 86.4x, Dec 2023 87.0x.

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold CHCT. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Christopher Davis | Davis Advisors | 0.03% | $5.9M | Reduced -2.2% |

## Insider purchases (SEC Form 4, open-market, last ~7 months)
2 purchases, $273K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-08-14 | Dupuy David H. | CEO and President | 10,000 | $151K | 15.13 | Too little history (no open-market trades in 2023) |
| 2026-08-11 | Hensley Robert Z | Director | 8,000 | $122K | 15.21 | Too little history (no open-market trades in 2023 or 2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | Piper Sandler | Target lowered | Neutral | $17 → $14 |
| 2026-10-09 | Truist Securities | Target lowered | Buy | $18 → $17 |
| 2026-09-21 | Evercore ISI Group | Target lowered | In-Line | $18 → $17 |
| 2026-08-06 | Piper Sandler | Target lowered | Neutral | $20 → $17 |
| 2026-08-06 | Evercore ISI Group | Target raised | In-Line | $17 → $18 |
| 2026-07-21 | Piper Sandler | Target raised | Neutral | $18 → $20 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +3.1% | -59.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +3.1% | -16.4% |
| Volatility (annualized) | 28.1% | 31.1% |
| Max drawdown | -32.0% (Jul 2026→Oct 2026) | -63.3% (Jan 2022→Oct 2025) |

## Peers (REIT - Healthcare Facilities)
XRN (Chiron Real Estate Inc.) USD 30.16 +4.61% · UHT (Universal Health Realty Income ) USD 37.81 +2.41% · MPT (Medical Properties Trust, Inc.) USD 2.71 +3.04% · DHC (Diversified Healthcare Trust) USD 7.87 +2.34% · LTC (LTC Properties, Inc.) USD 43.33 +2.70% · NHI (National Health Investors, Inc.) USD 66.96 +3.14%

## More
Full page: https://nexqual.com/CHCT · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Company outlook (8-K filed 2026-08-04)

- "Key strategic priorities for the next 18-24 months include occupancy improvement to 92%, portfolio reinvestment with 9-12% yields on capital, strategic capital recycling with over $70 million of marketed dispositions, and acquisition growth beginning with the current $99 million high-quality pipeline under contract with 9-10% expected yields and approximately 2.5% escalators."
- "Reallocating this capital is expected to provide an additional $25 million to $30 million of retained capital over the next two years to fund accretive acquisitions, portfolio reinvestments, and occupancy improvements."
- "While the transaction is progressing, the Company cannot provide assurance regarding the specific timing or the ultimate certainty of the closing. 1 • The Company has four properties under definitive purchase agreements, to be acquired after completion and occupancy, for an aggregate expected purchase price of approximately $99.0 million."
- "The Company's expected returns on these investments are approximately 9.1% to 9.75%."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | — | — | — | $31.5M | — |
| Next quarter (ends 2026-12-31) | — | — | — | $32.1M | — |
| Current fiscal year (ends 2026-12-31) | — | — | — | $126.3M | — |
| Next fiscal year (ends 2027-12-31) | — | — | — | $132.9M | — |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-03): ±8.9%; last 8 reports averaged ±5.5%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 28 | 37.0% | ±8.9% |
| 2026-12-18 | 56 | 32.8% | ±10.4% |
| 2027-01-15 | 84 | 40.7% | ±15.7% |
| 2027-04-16 | 175 | 32.8% | ±17.8% |